Back to Search
Start Over
Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma
- Source :
- Curr Oncol Rep
- Publication Year :
- 2020
- Publisher :
- Springer Science and Business Media LLC, 2020.
-
Abstract
- PURPOSE OF REVIEW: H3K27M is a frequent histone mutation within diffuse midline gliomas and is associated with a dismal prognosis, so much so that the 2016 CNS WHO classification system created a specific category of “Diffuse Midline Glioma, H3K27M-mutant”. Here we outline the latest pre-clinical data and ongoing current clinical trials that target H3K27M, as well as explore diagnosis and treatment monitoring by serial liquid biopsy. RECENT FINDINGS: Multiple epigenetic compounds have demonstrated efficacy and on-target effects in pre-clinical models. The imipridone ONC201 and the IDO1 inhibitor indoximod have demonstrated early clinical activity against H3K27M-mutant gliomas. Liquid biopsy of cerebrospinal fluid has shown promise for clinical use in H3K27M-mutant tumors for diagnosis and monitoring treatment response. SUMMARY: While H3K27M has elicited a widespread platform of pre-clinical therapies with promise, much progress still needs to be made to improve outcomes for diffuse midline glioma patients. We present current treatment and monitoring techniques as well as novel approaches in identifying and targeting H3K27M-mutant gliomas.
- Subjects :
- 0301 basic medicine
Oncology
Jumonji Domain-Containing Histone Demethylases
medicine.medical_specialty
Treatment response
Mutant
Antineoplastic Agents
Immunotherapy, Adoptive
Article
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Glioma
Panobinostat
Internal medicine
Humans
Medicine
Spinal Cord Neoplasms
Liquid biopsy
Cerebrospinal Fluid
Clinical Trials as Topic
Brain Neoplasms
business.industry
Liquid Biopsy
Prognosis
medicine.disease
Therapeutic monitoring
Histone Deacetylase Inhibitors
Clinical trial
030104 developmental biology
chemistry
030220 oncology & carcinogenesis
Mutation
business
Who classification
Subjects
Details
- ISSN :
- 15346269 and 15233790
- Volume :
- 22
- Database :
- OpenAIRE
- Journal :
- Current Oncology Reports
- Accession number :
- edsair.doi.dedup.....7b2fb58f150e39ae7da3df6d0b3bd3c3